Differences

This shows you the differences between two versions of the page.

--- bharat_biotech_covaxin [2021/11/15 20:13]
brian
+++ bharat_biotech_covaxin [2022/02/01 19:14] (current)
brian [Bharat Biotech COVAXIN® (BBV152)]
@@ Line 1: / Line 1: @@
+===== Bharat Biotech COVAXIN® (BBV152) =====
 Vaccine type:	Whole Virion Inactivated SARS-CoV-2 vaccine using a Vero Cell manufacturing platform\\
 Commercial name: COVAXIN® (BBV152)
@@ Line 6: / Line 8: @@
 URL:	https://www.bharatbiotech.com/	 	 \\
-WHO Approved for Emergency Use License: 03 November 2021
+WHO Approved for Emergency Use Listing: 03 November 2021((https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion))
 Route of administration:	Intramuscular	 \\
@@ Line 14: / Line 16: @@
 Preservative:	phenoxy ethanol	with concentration:	2.5 mg/dose
+[[https://www.bharatbiotech.com/images/covaxin/covaxin-factsheet.pdf|Factsheet]]
+====Preclinical Trials ====
 Preclinical Product Development September 12, 2020
 [[https://www.biorxiv.org/content/10.1101/2020.09.09.285445v2|link]]
@@ Line 23: / Line 27: @@
 [[https://www.nature.com/articles/s41467-021-21639-w|link]]
+==== Human Clinical Trials ====
 Human Clinical Trials – Phase I - Published: January 21, 2021
 [[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext|link]]
@@ Line 40: / Line 46: @@
 The phase 3 clinical trial results were published in the Lancet on November 11, 2021.\\
 [[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext#tables|Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial]]
+Posted December 29, 2021: [[https://www.medrxiv.org/content/10.1101/2021.12.28.21268468v1|Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study]]
+====Authorizations ====
+On January 3, 2021: India's Ministry of Health & Family Welfare announce a statement from DCGI - Central Standards Control Organization (CDSCO) Granting permission for emergency use of Covaxin.((https://www.bharatbiotech.com/images/press/bharat-biotech-covaxin-emergency-use-authorization-approval-by-dcgi-cdsco-moh-and-fw.pdf))((https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=ODA3Mw==))((https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/en/biotechver.pdf))((https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/cCOVAXIN-SMPC_BBIc.pdf))
+On November 5, 2021, Ocugen [[https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-submission-emergency-use-authorization|submitted]] Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
+On November 26, 2021 the US FDA put the application on [[https://ocugen.gcs-web.com/news-releases/news-release-details/ocugen-inc-provides-update-its-investigational-new-drug|hold]] for Covaxin and will advise what additional deficiencies are required to be corrected/fulfilled.
+====Other Studies ====
+Posted November 15, 2021: [[https://www.medrxiv.org/content/10.1101/2021.11.14.21266294v1.full-text|Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern]]
+Posted January 28, 2022: [[https://www.medrxiv.org/content/10.1101/2022.01.24.22269189v1|Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants]]
+====News ====